Advances in the clinical treatment of autoimmune hepatitis
-
摘要: 自身免疫性肝炎(AIH)是一种发病原因不明的由自身免疫介导的慢性进行性肝脏炎症性疾病。目前治疗AIH的主要目的是缓解症状,改善肝功能及病理组织异常,减慢向肝纤维化的进展。由于其容易复发,预后差异大,给治疗带来难度。近年来,AIH治疗方法主要有标准免疫抑制疗法,标准治疗无效的替代疗法或二线疗法,减轻副作用的中医药疗法,以及AIH末期或严重暴发性AIH的肝移植抢救疗法。对上述AIH治疗方法进行了系统综述,以期为临床应用提供参考。Abstract: Autoimmune hepatitis(AIH) is an autoimmune-mediated chronic progressive liver inflammatory disease with unknown pathogenesis. The main purpose of AIH treatment at present is to relieve symptoms,improve liver function and pathological abnormalities,and slow down the progression to liver fibrosis. Easy recurrence and a large difference in prognosis bring difficulties to the treatment of this disease. In recent years,AIH treatment methods mainly include standard immunosuppressive therapy,substitutive therapy or second-line therapy for ineffective standard therapy,traditional Chinese medicine treatment with reduced side effects,and liver transplantation rescue therapy for end-stage AIH or severe fulminant AIH. This article reviews the above treatment methods for AIH,in order to provide a reference for clinical application.
-
Key words:
- hepatitis,autoimmune /
- complementary therapies /
- liver transplantation /
- therapeutics
-
[1] WANG QX,YAN L,MA X. Autoimmune hepatitis in the AsiaPacific area[J]. J Clin Transl Hepatol,2018,6(1):48-56. [2] MACKAY IR. Historical reflections on autoimmune hepatitis[J]. World J Gastroenterol,2008,14(21):3292-3300. [3] ROBERTS SK,KEMP W. Salvage therapies for autoimmune hepatitis:A critical review[J]. Semin Liver Dis,2017,37(4):343-362. [4] FLOREANI A,RESTREPO-JIMNEZ P,SECCHI MF,et al.Etiopathogenesis of autoimmune hepatitis[J]. J Autoimmun,2018,95:133-143. [5] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. Autoimmune hepatitis:Standard treatment and systematic review of alternative treatments[J]. World J Gastroenterol,2017,23(33):6030-6048. [6] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识(2015)[J].临床肝胆病杂志,2016,32(1):9-22. [7] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004. [8] SONTHALIA N,RATHI PM,JAIN SS,et al. Natural history and treatment outcomes of severe autoimmune hepatitis[J]. J Clin Gastroenterol,2017,51(6):548-556. [9] LOWE D,JOHN S. Autoimmune hepatitis:Appraisal of current treatment guidelines[J]. World J Hepatol,2018,10(12):911-923. [10] LIWINSKI T,SCHRAMM C. Autoimmune hepatitis-update on clinical management in 2017[J]. Clin Res Hepatol Gastroenterol,2017,41(6):617-625. [11] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. [12] LU FB,HU ED,XU LM,et al. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis:A systematic review and network meta-analysis[J]. Exp Ther Med,2018,15(6):4838-4850. [13] JANMOHAMED A,HIRSCHFIELD GM. Autoimmune hepatitis and complexities in management[J]. Frontline Gastroenterol,2019,10(1):77-87. [14] CROPLEY A,WELTMAN M. The use of immunosuppression in autoimmune hepatitis:A current literature review[J]. Clin Mol Hepatol,2017,23(1):22-26. [15] HANOUNEH M,RITCHIE MM,ASCHA M,et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol,2019,54(1):76-80. [16] LEGUC,LEGROS L,KAMMERER-JACQUET S,et al.Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):290-291. [17] DOYCHEVA I,WATT KD,GULAMHUSEIN AF. Autoimmune hepatitis:Current and future therapeutic options[J]. Liver Int,2019,39(6):1002-1013. [18] TAUBERT R,HUPA-BREIER KL,JAECKEL E,et al. Novel therapeutic targets in autoimmune hepatitis[J]. J Autoimmun,2018,95:34-46. [19] JONES D,MANNS MP,TERRACCIANO L,et al. Unmet needs and new models for future trials in autoimmune hepatitis[J]. Lancet Gastroenterol Hepatol,2018,3(5):363-370. [20] PU SB,WANG JB,WANG RL,et al. Advantages and challenges of treatment on autoimmune hepatitis by traditional Chinese medicine and integrative medicine[J]. Chin J Exp Med Formul,2016,22(23):197-202.(in Chinese)浦仕彪,王伽伯,王睿林,等.中医和中西医结合治疗自身免疫性肝炎的优势与挑战[J].中国实验方剂学杂志,2016,22(23):197-202. [21] SHEN HZ,ZHANG L. Recent progress in integrated Chinese and Western medicine treatment of autoimmune hepatitis[J].Shanghai Med Pharm J,2019,40(5):6-9,70.(in Chinese)沈含章,张乐.自身免疫性肝炎及其中西医结合治疗的研究进展[J].上海医药,2019,40(5):6-9,70. [22] WANG Y,ZHENG W,MA JF,et al. Literature metrology research for the treatment of autoimmune hepatitis by traditional Chinese medicine[J]. Chin Arch Tradit Chin Med,2016,34(12):2861-2864.(in Chinese)王颖,郑炜,马俊福,等.中医药治疗自身免疫性肝炎的文献计量研究[J].中华中医药学刊,2016,34(12):2861-2864. [23] QIAN JH,WEI MM,SONG MD,et al. Characteristics and curative effect of TCM differentiation and treatment of autoimmune hepatitis[J]. Chin Arch Tradit Chin Med,2017,35(10):2651-2653.(in Chinese)钱金花,魏美美,宋梦蝶,等.自身免疫性肝炎的中医辨证治疗用药特点及疗效[J].中华中医药学刊,2017,35(10):2651-2653. [24] ZHU CJ,WU ZY,YE YY. Clinical effect of integrated traditional Chinese and Western medicine therapy for autoimmune hepatitis[J]. J Emerg Tradit Chin Med,2015,24(1):173-175.(in Chinese)朱常江,吴镇印,叶映月.中西医结合治疗自身免疫性肝炎的临床观察[J].中国中医急症,2015,24(1):173-175. [25] CHEN Y,WU ZZ,RUAN B. Clinical effect of integrated traditional Chinese and Western medicine therapy for autoimmune hepatitis:A meta-analysis[J]. Zhejiang J Integr Tradit Chin West Med,2019,29(3):244-250.(in Chinese)陈意,吴珍珠,阮冰.中西医结合治疗自身免疫性肝炎疗效的Meta分析[J].浙江中西医结合杂志,2019,29(3):244-250. [26] KERKAR N,YANNI G.‘De novo’and ‘recurrent’autoimmune hepatitis after liver transplantation:A comprehensive review[J]. J Autoimmun,2016,66:17-24. [27] CHO CW,KWON CHD,KIM JM,et al. Comparative analysis of the clinical outcomes of liver transplantation for probable and definite auto-immune hepatitis by international diagnostic scoring criteria[J]. Transplant Proc,2017,49(5):1126-1128. [28] STIRNIMANN G,EBADI M,CZAJA AJ,et al. Recurrent and de novo autoimmune hepatitis[J]. Liver Transpl,2019,25(1):152-166.
本文二维码
计量
- 文章访问数: 1349
- HTML全文浏览量: 46
- PDF下载量: 260
- 被引次数: 0